What Is Aqvesme, and Why Does It Matter? Aqvesme (mitapivat) is a new oral medicine approved by the FDA for treating anemia in adults with alpha- or beta-thalassemia, including those who need and ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both non-transfusion- and transfusion-dependent patients with alpha- or beta-thalassemia, ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...

Thalassemia is a hereditary blood disorder marked by impaired hemoglobin production, often resulting in chronic anemia, fatigue, and repeated medical interventions. While modern medicine offers ...

The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, ...

It is concerning that many people have experienced problems with haemoglobin due to haemoglobinopathies (genetically altered and/or synthesised mutations), and that most hemoglobinopathies are missed ...

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) shares climbed 19.97%, closing at $29.50, up $4.91, after the U.S. Food and Drug Administration approved AQVESME (mitapivat) as an oral treatment for ...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or ...

When I was about 6 years old in the early ‘40s, my 16-year-old brother was sent to a sanitarium for tuberculosis patients. He ...

Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, ...